BOSTON — Verastem Oncology (Nasdaq: VSTM) said it granted stock options to purchase 73,000 shares of common stock to eight new employees and awarded 218,265 restricted stock units to 19 new employees. The awards were made under the Nasdaq inducement grant exception pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees’ acceptance of employment.
The stock options carry an exercise price of $6.88 per share, equal to Verastem Oncology’s closing common stock price on Nasdaq on January 6, 2026. The options and restricted stock units vest 25% on the one-year anniversary of each employee’s hire date, with the remaining shares vesting in equal quarterly installments over the following three years, subject to continued service as an employee or other service provider to the company.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company developing and commercializing medicines for patients with RAS/MAPK pathway–driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. and is advancing a pipeline of small-molecule drugs targeting pathways that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, visit www.verastem.com and follow the company on LinkedIn.
Leave a Reply